Bitterroot Australia

Bitterroot Bio is a clinical-stage biotechnology company pioneering the field of immunocardiology to develop transformative therapies for cardiovascular disease. Founded by world-leading experts from Stanford University, the company targets the CD47 don't eat me signaling pathway to address the underlying causes of atherosclerosis. Their lead program, a monoclonal antibody, is designed to promote the clearance of pro-inflammatory cells within arterial plaques while minimizing the hematologic side effects typically associated with CD47 inhibition. By leveraging the body's innate immune system, Bitterroot Bio aims to provide new treatment options for patients with high-risk vascular conditions who are underserved by current lipid-lowering therapies. The company maintains a significant presence in Australia to conduct clinical research and development activities.